Intercept Pharma (ICPT) Tops Q3 EPS by 42c, Revenues Miss; Offers FY18 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to Intercept Pharma (ICPT) Tops Q3 EPS by 42c, Revenues Miss; Offers FY18 Revenue Guidance

Intercept Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

October 31, 2018 7:05 AM EDT

Worldwide Ocaliva net sales of $46.6 million in the third quarter of 2018Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver fibrosis expected to report data in the first half of 2019

Conference call scheduled for 8:30 a.m. ET today

NEW YORK, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended September 30,... More